The Food and Drug Administration had recently approved a new drug for the treatment of atopic dermatitis (eczema), which can ...
The U.S. Food and Drug Administration has approved Indianapolis-based Eli Lilly's new treatment for moderate to severe eczema ...
Dupilumab decreases general and type 2 inflammatory biomarker levels in children with moderate to severe atopic dermatitis.
Healthcare Asia on MSN3d
Atopic dermatitis market to reach $16.7b by 2030 across seven major marketsPharmaceutical firms are urged to capitalise on current trends in AD trials. The atopic dermatitis (AD) market is projected ...
A new single-dose autoinjector presentation of Adbry ® (tralokinumab-ldrm) is now available for use in the treatment of moderate to severe atopic dermatitis not adequately controlled with topical ...
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has commenced its Phase 2a clinical trial for ATI-2138, an innovative oral covalent ...
The U.S. Food and Drug Administration has approved Eli Lilly's Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 ...
Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...
LEO Pharma Inc. announced today the availability of the Adbry® (tralokinumab-ldrm) 300 mg/2 mL single-dose autoinjector in ...
Eli Lilly and Co.’s Ebglyss (lebrikizumab) becomes the latest U.S. entrant in the increasingly competitive atopic dermatitis space, following FDA approval of the IL-13-targeting antibody, which will ...
Three years after establishing an immunology unit, Eli Lilly has gained its third FDA approval in the specialty area as the U ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback